Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Livia Andrade et al.|Annals of Oncology|2021Cited by 724
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical OncologyFederica Miglietta, Stefania Gori, Michela Cinquini et al.|The Breast|2022Cited by 16
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancerLuca Licata, Giuseppe Curigliano, Maria Vittoria Dieci et al.|Cancer Treatment Reviews|2024Cited by 11
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectivesStefania Gori, Riccardo Gerosa, Michela Cinquini et al.|Tumori Journal|2025Cited by 1
HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapySara Pizzamiglio, Serena Di Cosimo, Adriana Blanda et al.|npj Breast Cancer|2025Cited by 1